ReviewNaunyn-Schmiedeberg's archives of pharmacology2026
Finn Waagstein and the paradigm shift in the treatment of heart failure with β-adrenergic receptor antagonists ('β-blockers').
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ursula Ravens - recipient of the Schmiedeberg Medal: a distinguished career dedicated to cardiovascular pharmacology and cardiac electrophysiology.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Targeting the heart-immune axis after myocardial infarction: from inflammation to immunomodulation.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Beta-adrenergic receptor antagonists, formerly called 'β-blockers' (which name will be used throughout this historical review), were initially used for their antihypertensive, anti-ischemic, and antiarrhythmic effects. In the early 1970s, the Swedish cardiologist Finn Waagstein opposed the paradigm that β-blockers were contraindicated in patients with decompensated heart failure. This review retraces the exciting paths of Waagstein's personal fight for recognition of his successful therapy of cardiac decompensation in patients with acute myocardial infarction and also of heart failure. In the second part, we summarise the clinical trials that led to the slow acceptance by the scientific community of the paradigm shift from contraindication to first-line treatment with β-blockers in heart failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.